CPLX4: A Potential Drug Target and Biomarker (G339302)

Target Name: CPLX4

NCBI ID: G339302

CPLX4

CPLX4: A Potential Drug Target and Biomarker

CPLX4 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the CPLX family, which includes several similar proteins that play important roles in cellular signaling. One of the unique features of CPLX4 is its ability to interact with several different signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This makes it an attractive target for drug development, as it can be used to treat a wide range of diseases.

CPLX4 Functions as a Negative regulators of TGF-β Signaling

TGF-β is a well-known signaling pathway that plays a crucial role in cellular growth, differentiation, and repair. It is involved in many important processes in the body, including cell proliferation, migration, and angiogenesis. However, TGF-β signaling can also contribute to the development of many diseases, including cancer, neurodegenerative diseases, and developmental disorders.

CPLX4 is a negative regulator of TGF-β signaling. It can inhibit the activity of the TGF-β receptor, which is a key component of the pathway. This inhibition can lead to the inhibition of TGF-β-induced signaling, and as a result, the regulation of cellular processes that are dependent on TGF-β signaling. This can have a positive impact on the development and progression of many diseases.

CPLX4 as a Potential Drug Target

CPLX4 is a drug target that has the potential to treat a wide range of diseases. Its ability to interact with multiple signaling pathways makes it an attractive target for small molecules that can inhibit its activity. One of the challenges in developing a drug target for CPLX4 is its diverse expression pattern, as it is expressed in many different tissues of the body. However, research is ongoing to identify small molecules that can inhibit its activity and have the potential to treat various diseases.

CPLX4 as a Biomarker

CPLX4 is also a potential biomarker for several diseases. Its ability to interact with multiple signaling pathways makes it a useful target for the development of diagnostic tests for diseases associated with these pathways. For example, CPLX4 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, CPLX4 has been associated with cancer, and studies have shown that it can be used as a potential biomarker for cancer progression.

Conclusion

In conclusion, CPLX4 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Its ability to interact with multiple signaling pathways makes it an attractive target for small molecules that can inhibit its activity. Further research is needed to identify small molecules that can inhibit CPLX4 activity and to develop diagnostic tests for diseases associated with its expression. Once these resources are identified, CPLX4 may have the potential to treat a wide range of diseases.

Protein Name: Complexin 4

Functions: Complexin that regulates SNARE protein complex-mediated synaptic vesicle fusion (By similarity). Required for the maintenance of synaptic ultrastructure in the adult retina (By similarity). Positively regulates synaptic transmission through synaptic vesicle availability and exocytosis of neurotransmitters at photoreceptor ribbon synapses in the retina (By similarity). Suppresses tonic photoreceptor activity and baseline 'noise' by suppression of Ca(2+) vesicle tonic release and the facilitation of evoked synchronous and asynchronous Ca(2+) vesicle release (By similarity)

The "CPLX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPLX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets